Mankind Pharma

2,398.05
+25.90
(1.09%)
Market Cap
97,867.10 Cr
EPS
47.75
PE Ratio
48.47
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
3,054.80
52 Week Low
1,901.05
PB Ratio
7.29
Debt to Equity
0.02
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from14 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy+71.43 %
+71.43 %
Hold+14.29 %
+14.29 %
Sell+14.29 %
+14.29 %

Company News

View All News
Caret
positive
Mankind Pharma Upgraded in FTSE All World Index4 days ago
Mankind Pharma has received a weight upgrade in the FTSE All World Index, resulting in an expected inflow of $16.0 million (approximately 1.3 billion rupees) into the stock.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,764.75 4,28,233.30 35.92 49,887.20 12.06 9,648 13.77 61.58
5,840.65 1,56,910.50 74.97 8,184.00 0.89 1,600 64.53 55.23
1,511.20 1,23,084.40 24.45 26,520.70 14.17 4,155 47.38 60.28
3,245.05 1,10,720.70 58.75 10,785.70 11.59 1,656 13.54 61.68
1,177.90 1,00,988.70 18.34 28,905.40 12.36 5,578 1.69 51.86
2,398.05 97,867.10 48.47 10,615.60 19.57 1,942 -16.38 56.07
2,068.75 96,711.60 32.93 20,141.50 19.94 1,936 38.82 54.50
907.35 92,945.80 20.14 19,831.50 13.82 3,831 29.92 48.54
1,194.95 70,253.80 19.68 29,559.20 17.55 3,169 -10.04 61.05
31,101.85 66,026.50 49.49 6,097.20 10.80 1,201 16.01 61.04
Growth Rate
Revenue Growth
19.57 %
Net Income Growth
48.26 %
Cash Flow Change
18.70 %
ROE
18.04 %
ROCE
13.14 %
EBITDA Margin (Avg.)
16.05 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,764
2,200
2,457
2,130
2,103
2,642
2,772
2,682
2,536
2,998
3,189
3,311
Expenses
1,441
1,724
1,835
1,654
1,636
1,924
2,025
2,000
1,850
2,212
2,227
2,400
EBITDA
323
476
622
477
467
718
746
681
686
786
962
911
Operating Profit %
17 %
21 %
24 %
21 %
20 %
25 %
25 %
23 %
24 %
24 %
28 %
26 %
Depreciation
47
78
79
85
85
87
97
110
105
108
106
192
Interest
13
16
10
13
5
6
9
9
9
11
7
221
Profit Before Tax
263
382
533
379
377
625
641
562
572
668
849
497
Tax
70
84
110
83
84
130
130
103
95
125
190
113
Net Profit
193
298
423
296
294
494
511
460
477
543
659
385
EPS in ₹
4.74
7.30
10.48
7.09
7.13
12.15
12.51
11.33
11.76
13.39
16.31
9.45

Balance Sheet

Balance Sheet
2022
2023
2024
Total Assets
9,148
9,715
11,963
Fixed Assets
3,588
4,251
4,545
Current Assets
4,407
4,328
6,568
Capital Work in Progress
702
550
282
Investments
1,110
1,346
2,568
Other Assets
3,749
3,568
4,568
Total Liabilities
9,148
9,715
11,963
Current Liabilities
2,624
1,863
2,120
Non Current Liabilities
208
229
268
Total Equity
6,316
7,623
9,576
Reserve & Surplus
6,115
7,395
9,323
Share Capital
40
40
40

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
Net Cash Flow
103
-92
156
22
77
Investing Activities
-436
-1,222
-1,369
-1,052
-2,081
Operating Activities
1,070
1,137
920
1,813
2,152
Financing Activities
-531
-8
605
-740
5

Share Holding

% Holding
Sept 2022
Mar 2023
May 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
79.00 %
76.50 %
76.50 %
76.50 %
76.50 %
76.50 %
74.88 %
74.87 %
74.87 %
72.71 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.87 %
11.58 %
12.37 %
13.34 %
DIIs
0.00 %
2.64 %
2.64 %
4.64 %
4.39 %
9.49 %
11.14 %
9.95 %
9.90 %
11.06 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.15 %
4.15 %
1.02 %
1.11 %
1.14 %
1.22 %
1.46 %
1.55 %
1.60 %
Others
21.00 %
16.71 %
16.71 %
17.83 %
18.00 %
12.87 %
2.89 %
2.15 %
1.31 %
1.30 %
No of Share Holders
17
4,02,322
4,02,322
1,31,918
1,34,731
1,27,449
1,35,116
1,53,450
1,63,854
1,72,431

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Credit Rating
6 hours ago
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Mar 01, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 28, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 28, 2025
Update On Scheme Of Arrangement For Amalgamation Of Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma Limited
Feb 27, 2025
Update On Scheme Of Arrangement For Amalgamation Of Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma Limited
Feb 27, 2025
Announcement under Regulation 30 (LODR)-Credit Rating
Feb 25, 2025
Announcement under Regulation 30 (LODR)-Credit Rating
Feb 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 20, 2025
Announcement under Regulation 30 (LODR)-Change in Directorate
Feb 18, 2025
Final Update On Stake Sale Of Mahananda Spa And Resorts Private Limited
Feb 11, 2025
Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
Feb 10, 2025
Board Meeting Outcome for Mankind Pharma Limited Has Informed The Exchange Regarding Sale Of Entire Stake In Mahananda Spa And Resorts Private Limited
Feb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 06, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Feb 04, 2025
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Jan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 24, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Jan 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper Publication
Jan 24, 2025
Announcement under Regulation 30 (LODR)-Investor Presentation
Jan 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 23, 2025
Statement Under Regulation 32 Of The Listing Regulations.
Jan 23, 2025
Integrated Filing (Financial)
Jan 23, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. January 23 2025.
Jan 23, 2025
Intimation Regarding Redemption Of Commercial Paper
Jan 16, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Jan 15, 2025
Commercial Paper-Quarterly Certificate December 2024
Jan 14, 2025
Intimation Of Record Date For Redemption Of Commercial Paper Issued By The Company
Jan 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 14, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And 50 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Jan 13, 2025
Announcement Under Regulation 30 Of SEBI LODR
Jan 08, 2025
Appointment of Company Secretary and Compliance Officer
Jan 08, 2025
Announcement under Regulation 30 (LODR)-Cessation
Jan 08, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. January 8 2025
Jan 08, 2025
Creation Of Pledge On The Shares Of Bharat Serums And Vaccines Limited
Jan 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 06, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) 2015
Dec 28, 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Dec 27, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Dec 23, 2024
Announcement under Regulation 30 (LODR)-Qualified Institutional Placement
Dec 16, 2024
Outcome Of The Board Meeting Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dec 16, 2024
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dec 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dec 04, 2024
Appointment of Company Secretary and Compliance Officer
Dec 03, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. December 3, 2024
Dec 03, 2024
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations)
Nov 22, 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Nov 22, 2024
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Nov 21, 2024

Technical Indicators

RSI(14)
Neutral
56.07
ATR(14)
Less Volatile
92.95
STOCH(9,6)
Neutral
57.38
STOCH RSI(14)
Overbought
93.18
MACD(12,26)
Bullish
30.62
ADX(14)
Strong Trend
25.94
UO(9)
Bearish
59.08
ROC(12)
Uptrend And Accelerating
5.44
WillR(14)
Overbought
-15.51

About Mankind Pharma

Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(1 Years, 45 days)
Chairperson NameRAMESH CHAND JUNEJA